by Cell Therapy Market, By Type (Autologous and Allogeneic), By Therapy (Mesenchymal Stem Cell Therapy, Fibroblast Cell Therapy, Hematopoietic Stem Cell Therapy, and Other Therapies), By Application (Musculoskeletal, Malignancies, Cardiovascular, Dermatology and Wounds, and Other Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028.
Market Overview:
Cell therapy refers to the use of living cells to treat or prevent diseases by restoring or replacing damaged or dysfunctional cells within the body. It is a branch of regenerative medicine that aims to harness the reparative or regenerative properties of cells to promote healing and restore normal physiological function.
Competitive Landscape:
Major players operating in the global cell therapy market include Takeda Pharmaceutical Company Limited (TiGenix), Gilead Sciences Inc. (Kite Pharma Inc.), Allogene Therapeutics Inc., Vericel Corporation, Novartis AG, Organogenesis Inc., Dendreon Pharmaceuticals LLC, Nipro Corporation, Medipost Co. Ltd., and Stempeutics Research Pvt. Ltd.
Key Market Drivers:
The increasing incidence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes, has created a significant need for innovative and effective treatment options. Cell therapy offers a promising approach by providing regenerative and reparative capabilities to damaged tissues and organs, driving its adoption. This is expected to augment the growth of the global Cell Therapy Market .
Significant advancements in cell culture techniques, cell engineering, and cell preservation have enhanced the efficacy and safety of cell therapy products. The development of induced pluripotent stem cells (iPSCs) and genome editing technologies, such as CRISPR-Cas9, has further expanded the therapeutic potential of cell therapy. For instance, in January 2022, Immunocore got the approval of the U.S. Food and Drug Administration, for its KIMMTRAK (tebentafusp-tebn), which will be used for treating metastatic or unresectable uveal melanoma.
Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in research and development activities related to cell therapy. The focus on developing novel cell therapy products, optimizing manufacturing processes, and conducting clinical trials is estimated to enhance the growth of the global cell therapy market.
Regulatory agencies in various countries are streamlining the approval processes for cell therapy products. The establishment of clear guidelines and regulatory frameworks has facilitated the commercialization of cell therapies, encouraging market growth.
Covid-19 Impact Analysis:
During the COVID-19 pandemic, the development of cell-based therapies, such as mesenchymal stem cells (MSCs), for treating COVID-19 patients gained significant attention. Additionally, the pandemic highlighted the need for cell therapy manufacturing facilities and infrastructure to ensure the timely and efficient production of cell therapies in response to future outbreaks. This boosted the growth of the global cell therapy market. For instance, in August 2020, the United States Food and Drug Administration gave approval to Novartis AG’s Novartis Kesimpta, which is a targeted B-cell therapy used for relapsing multiple sclerosis.
Key Takeaways:
North America is expected to dominate the growth of the global cell therapy market, owing to the factors such as well-established healthcare infrastructure, extensive research and development activities, and supportive regulatory frameworks. The United States accounts for the largest share in this region. For instance, in March 2019, SpinalCyte LLC. Introduced an advanced comprehensive resource for increasing the benefits of regenerative medicine technology.
Europe is estimated to witness high growth in the global cell therapy market, owing to the increasing investments in regenerative medicine, strong collaborations between academic institutions and industry, and favorable reimbursement policies. Countries like Germany, the UK, and Switzerland are key contributors to the regional market. For instance, in March 2021, the United States Food and Drug Administration gave approval to Novadip Biosciences’s NVD-003, which is a regenerative bone product used to treat rare pediatric bone illnesses.
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
